Cocrystalline DHEA formulations
US10130713B2 · kind B2 · utility
0Cited by
1References
15Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Apr 21, 2014 |
| Grant date | Nov 20, 2018 |
| Priority date | — |
| Expiry date | Apr 21, 2034 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07B2200/13
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A cocrystalline DHEA composition with at least one additional coformer is disclosed for therapeutic formulations. The cocrystalline DHEA/coformer formulation including at least one coformer chosen from the group consisting of glutaric acid, maleic acid, tartaric acid, fructose, and wherein the L-isomer of tartaric acid and the D-isomer of fructose are utilized. The cocrystalline DHEA/coformer formulations include certain excipients as a solubilizer or inhibitor.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.